• Tonix began enrolling patients in HORIZON, a potentially pivotal Phase 2 trial of TNX-102 SL as a first-line monotherapy for major depressive disorder.
• No results have been presented; the trial is designed to assess whether the drug improves depressive symptoms over six weeks.
• The study targets sleep disruption as a treatment lever in depression, extending use of the same drug marketed as TONMYA for fibromyalgia.
• Tonix expects about 360 patients across roughly 30 U.S. sites, a scale that could support later-stage development decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-030408), on June 29, 2026, and is solely responsible for the information contained therein.